Sheela Prasad

Sheela Prasad, PhD, is an accomplished Investment Analyst at Marshall Wace, specializing in therapeutics long/short equity since October 2020. Previously, Prasad worked as an Equity Research Associate in Biotechnology at Piper Jaffray, where responsibilities included financial statement analysis and due diligence. Prasad gained significant research experience at The University of Chicago, managing the National Collaborative Chicago Based Congenital Toxoplasmosis Study and contributing to academic literature. Early research work was performed at Penn Medicine, focusing on advanced brain research protocols. Prasad holds a Ph.D. in Molecular Pharmacology from NYU School of Medicine and a BA in Economics, Neuroscience, and Healthcare Management from the University of Pennsylvania, along with being a Level II Candidate in the CFA Program.